Board Stats

Bristol-Myers Squibb Co.

Y! CELG MM R&D deep dive CELG legacy IV board (still active) CELG legacy IV board (premium) @bmsnews (Company Twitter Account) GoFundMe Mike Barnett Recovery Fund

BMY / Message Board

BOARD

GROUPS

Written By On Topic Only -- All Messages

Hide Replies

Keyword
Subject

Between			and
Rec'd By

Authored By
Minimum Recs

MSG #	SUBJECT	TYPE	AUTHOR	SENTIMENT	RECS	DATE POSTED
8831	Re: Cowen - 20 EVENTS IN 2022 THAT COULD CHANGE PRACTICE, ALTER COMPANIES, MOVE STOCKS	GN	Doolen		2	1/16/2022 7:58:31 AM

8830	Cowen - 20 EVENTS IN 2022 THAT COULD CHANGE PRACTICE, ALTER COMPANIES, MOVE STOCKS	GN	JBWIN		16	1/15/2022 4:35:40 PM

8829	Adagene Announces First Patients with Advanced Non-Small Cell Lung Cancer Dosed in Phase 1b/2 Clinical Trial of ADG106 in Combination with Nivolumab in Singapore	GN	jerrykrause		3	1/15/2022 12:16:17 PM

8828	Re: All indices are in dark red but big pharma are either green or fractional loss! Pricing pressure seems to be absent.	GN	Biotech2050		3	1/14/2022 11:10:21 AM

8827	All indices are in dark red but big pharma are either green or fractional loss! Pricing pressure seems to be absent.	GN	teflon2000		1	1/14/2022 10:55:09 AM

8826	Reblozyl article in OncLive	GN	Biotech2050		8	1/13/2022 6:00:45 AM

8825	Building IP: BMY Patent Application re "SMALL MOLECULE INHIBITORS OF GALECTIN-3"	GN	JBWIN		2	1/13/2022 12:56:39 AM

8824	Building IP: CELG Patent Application re "3-(4-((4-(MORPHOLINOMETHYL-BENZYL)OXY)-1 -OXOISOINDOLIN-2-YL)PIPERIDINE-2,6-DIONE FOR THE TREATMENT OF SYSTEMIC LUPUS ERYTHEMATOSUS"	GN	JBWIN		1	1/13/2022 12:54:38 AM

8823	Building IP: Juno Therapeutics Patent Application re "METHODS OF DOSING ENGINEERED T CELLS FOR THE TREATMENT OF B CELL MALIGNANCIES"	GN	JBWIN		1	1/13/2022 12:52:27 AM

8822	Building IP: Juno Therapeutics Patent Application re "METHODS AND COMBINATIONS FOR TREATMENT AND T CELL MODULATION"	GN	JBWIN		1	1/13/2022 12:51:11 AM

Go to Msg #

BOARDS Sign In for Filters